Background and Purpose: Carotid atherosclerotic thrombosis is an important cause of ischemic stroke in Western countries. The therapeutic efficacy of either aspirin or heparin alone in this setting is still controversial. Recently we developed a simple model, the "clamp" method, to induce acute carotid mural thrombosis in vivo in guinea pigs. In this study, we used this model to evaluate the antithrombotic effects of aspirin, heparin, and their combination.
Methods: Sixty-four male guinea pigs were divided equally into control, aspirin, heparin, and combined groups. Physiological saline, aspirin (5 mg/kg body wt), heparin (200 units/kg body wt), or a combination of aspirin and heparin, respectively, was injected via the jugular vein before the use of the clamp method. Thirty minutes after the injection of saline or drug(s), Pean's forceps was used to clamp the carotid artery at a tangent angle for 3 minutes. One hour later, the carotid artery was resected and prepared for observation under a scanning electron microscope or light microscope to evaluate the degree of mural thrombosis.
Results: The results showed that the combination of aspirin and heparin had an excellent effect in inhibiting in vivo acute carotid thrombosis (p<0.001) and was significantly better than the effect of aspirin alone (p<0.01) or heparin alone (p<0.01).
Conclusions: Our study clearly demonstrated that the combined use of aspirin and heparin produced a much better antithrombotic effect than either agent alone at sites of carotid endothelial injury when given before the injury. This combined regimen may be useful clinically in acute Under scanning electron microscopy, the thrombi were recognized at lower magnification (x43-100) as abnormal mural masses or materials containing fused platelet aggregates, deformed platelets, crenated erythrocytes, fibrils, and scanty leukocytes, which were identified under higher magnification (x 1,000-5,000). The degree of mural thrombosis of a carotid specimen under scanning electron microscopy was evaluated in two ways. First, it was expressed as the total surface area (in square millimeters) of thrombi seen in that specimen, calculated by the AUTOCAD computer program with the aid of a digitizer. Second, it was graded by the extent that the edges of endothelial laceration were covered by thrombi. According to the latter system, the degree of carotid mural thrombosis was classified into three categories: 1) marked, with the edges of endothelial laceration completely or almost completely covered by thrombi; 2) moderate, with the edges of endothelial laceration partially covered by thrombi; and 3) mild, with the edges of endothelial laceration completely or almost completely free from thrombi.
The carotid specimens were prepared for observation under a light microscope as follows. Specimens were fixed in formalin for at least 8 hours. Then, they were cut longitudinally into three smaller pieces. The three cut surfaces were prepared as thin pathological slides and stained with hematoxylin and eosin. In this preparation, the cross section of the endothelial laceration and the thrombi in or overlying the laceration could be seen. The one cut surface with the largest endothelial laceration was taken to represent the specimen. The thrombi were recognized as abnormal pink fibrillary materials or masses associated with interrupted endothelia, containing some erythrocytes and occasionally leukocytes. Fibrin fibers in the thrombi could be identified by phosphotungstic acid-hematoxylin stain. The degree of mural thrombosis was then evaluated by the following two parameters: 1) maximal width of thrombus divided by width of laceration and 2) height of thrombus (in millimeters) above the endothelial level protruding into the carotid lumen.
Ex vivo platelet aggregation, PT, and APTT were studied in 10 of 16 guinea pigs in each group. The ex vivo platelet aggregation tests were done as follows. Immediately after resection of the right common carotid artery, 9 mL of blood was drawn from the left common carotid artery directly into a 10-mL syringe containing 1 mL of 3.8% sodium citrate. It was mixed well and separated into two tubes, 5 mL in each, which were then centrifuged at room temperature at 90g for 10 minutes to obtain platelet-rich plasma (PRP). The collagen. The final concentrations of collagen used in PRP were 1, 2, 4, and 10 ,ug/mL. We used collagen as the platelet activator because our previous studies had shown that the mural thrombi of our model formed on subendothelial collagen fibers'4 and that collagen-induced platelet aggregation was more similar between humans and guinea pigs than that induced by other platelet activators. 15PT and APTT were measured by a computer-controlled, 10-channel coagulation analyzer (Behring Fibrintimer 10, Behringwerke AG, Marburg, FRG). All the above measurements, including the degree of mural thrombosis, were performed randomly but not in a blinded manner.
Lysine acetylsalicylic acid powder (containing 0.5 g aspirin in a mixture of 0.9 g lysine aspirin and 0.1 g glycine) was purchased from China Chemical and Pharmaceutical Co. Ltd., Taiwan, ROC. Heparin (5,000 units/mL) was obtained from Novo Industrial Co. Ltd., Denmark. Collagen (bovine achilles tendon, type I) was obtained from Sigma Chemical Co., St. Louis, Mo. The kit reagents for measuring PT and APTT were purchased from Behringwerke AG.
The results of control, aspirin, heparin, and combined groups were compared either by Student's t test using mean+SEM or by the Mantel-Haenszel x2 test.
Results
The results of ex vivo platelet aggregation tests (Table  1) showed the following. 1) Platelet aggregations in the aspirin group were significantly less than those in the control group except for that induced by the highest concentration of collagen (10 ,ug/mL). 2) Platelet aggregations in the heparin group were, in general, less than those in the control group, but a significant difference was found only in that induced by 2 1g/mL of collagen.
3) Platelet aggregations in the combined group were significantly less than those in the control group. 4) Comparing the combined and the aspirin groups, platelet aggregations were, in general, less in the combined group. These results confirmed the antiplatelet effect of The results of PT and APTT measurements (Table 2 ) showed the following. 1) In the heparin-treated groups, PT and APTT were both significantly prolonged compared with those in the control group. 2) The prolongation of APTT was much more prominent than that of PT. 3) There was no difference in the values of PT and APTT between the aspirin and the control groups. These results indicated that the coagulation system of guinea pigs was not significantly affected by aspirin but was significantly affected by heparin, similar to the effect in humans.
Photographs of carotid specimens in the control group ( Figure 1A and 1B) , the aspirin group ( Figure  1C) , the heparin group ( Figure 1D) , and the combined group ( Figure 1E and 1F) taken under a scanning electron microscope are shown in Figure 1 . From these photographs, the total surface area of thrombi (in square millimeters) could be estimated and the extent that the edges of the endothelial laceration were covered by thrombi could be determined. Table 3 shows that the total surface areas of thrombi in the aspirin, heparin, and combined groups were all significantly smaller than that in the control group (p<O.O5,p<0.05, and p<O.OO1, respectively). The total surface area of thrombi in the combined group was the smallest among the four groups and was significantly smaller than that in the aspirin group (p<O.O1) and the heparin group (p <0.05). Table 4 shows the results of comparing carotid mural thrombosis by observing the extent that the edges of endothelial laceration were covered by thrombi under scanning electron microscopy. The degree of mural thrombosis was classified into three grades (marked, moderate, and mild), as described in "Materials and Methods." By Mantel-Haenszel x2 test (2x2) (see Table 4 ), we found that mural thrombosis was most markedly suppressed in the combined group. The suppression of mural thrombosis in the aspirin and heparin groups was weak, although statistically significant, compared with the results of the control group.
Photographs of carotid specimens in the control group (Figure 2A and 2B) , the aspirin group ( Figure  2C ), the heparin group ( Figure 2D) , and the combined group ( Figure 2E and 2F) taken under a light microscope are shown in Figure 2 . From these photographs, the width of endothelial laceration and thrombus, the ratio of maximal width of thrombus to width of laceration, and the height of thrombus protruding into the carotid lumen could be measured. Table 5 shows the results of these measurements. The ratios of maximal width of thrombus to width of laceration in the aspirin and the combined groups were significantly smaller than Tables 3, 4 , and 5. In our study, we also found that the antithrombotic effect of either aspirin or heparin alone was limited, although statistically significant. This finding might partially explain the controversial results of those clinical trials using aspirin or heparin alone to treat acute ischemic stroke.
In the arterial system characterized by rapid flow and a high shear rate of blood, platelets are believed to play a more important role than coagulation factors in initiating acute thrombosis.12,21 On the other hand, coagulation factors are thought to play the major role in developing thrombosis of the venous system when blood stasis is present.'8 In a severely diseased or injured artery, a special condition of having both rapid turbulent flow and focal blood stasis may exist, and coagulation factors may become as important as platelets in promoting acute thrombosis. Aspirin or heparin alone in such a circumstance may have only a limited effect in inhibiting thrombus formation. The limited effect of aspirin alone may be due to the fact that it has no direct anticoagulant action, and it cannot inhibit platelet aggregation induced by thrombin, which could be produced locally in a diseased and stenosed artery.21-23The limited effect of heparin alone may be due to the fact that it has no direct antiplatelet action, and it has a platelet proaggregatory property, which has been reported for years.24,25 Thus, the reasons that a combina- Table  5 , several data were interesting and worth further discussion. The width of endothelial laceration in the combined group (0.19+0.03 mm, n=6) was significantly smaller than that in the control group (0.42±0.06 mm, n =6,p<0.005), but the standard errors were both small. These data indicated that the intragroup difference in the width of laceration was small within either the control or the combined group, but the intergroup difference was large between the control and the combined groups. To understand the reason for this unexpected finding, we later again observed all specimens of all groups under light microscopy. A possible explanation was that the endothelial laceration in the control group was wider because the bilateral edges of laceration had been pushed outward by the large thrombus formed in the laceration. Therefore, the shape of laceration in the control group often looked like a shallow dish in cross section (Figure 2A and 2B ). In contrast, the shape of endothelial laceration in the combined group often looked more like a deep bowl ( Figure 2E and 2F), probably because there was no or only minimal thrombus in the laceration, and the two edges of laceration would come closer when the carotid segment shortened immediately after being resected away from the neck.
In view of the excellent antithrombotic effect of combining aspirin and heparin in the study, we propose that this combined regimen may be valuable in the clinical field. Clinically it is usually not possible to treat an acute thrombotic event before its onset, as has been done in our In conclusion, our study clearly demonstrated that combined use of aspirin and heparin produced a much better antithrombotic effect than either agent alone at sites of carotid endothelial injury when given before the injury. This combined regimen may be useful clinically in acute carotid thrombosis secondary to carotid endarterectomy or carotid diseases. Clinical trials to evaluate its therapeutic efficacy and the possible risk of hemorrhagic infarction are needed.
